Genetic testing is of importance as it ensures, (1) an accurate diagnosis of ARHR2, (2) exclusion of ENPP1 deficiency in patients with hypophosphatemic rickets being considered for burosumab therapy, and (3) diagnosis/exclusion of additional genetic conditions (ie, hypophosphatasia). This evidence concerns the gene ENPP1 and hypophosphatasia.